Načítá se...
Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88(L265P) plasmablasts in vivo
The MYD88(L265P) mutation is found in 2% to 10% of chronic lymphocytic leukemia, 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenström macroglobulinemia, making it conceptually attractive to treat these malignancies with inhibitors of endosomal Toll-like receptors (TLR9,...
Uloženo v:
| Vydáno v: | Blood |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034740/ https://ncbi.nlm.nih.gov/pubmed/27458005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-03-708065 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|